Intellia Therapeutics, Inc.

Listed Company

NTLACIK 0001652130NasdaqLarge AcceleratedIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$67.67M

Net Income

$-412.69M

Total Assets

$842.13M

Equity

$671.39M

Shares Out

139.72M

Op. Cash Flow

$-394.74M

NTLA$11.38−3.81% · past yearDBEQ Basic

Daily closing prices

Business

Intellia Therapeutics is a biopharmaceutical company developing in vivo CRISPR-based gene editing therapies. The company's lead programs are lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis, both in Phase 3 clinical development and designed to deliver durable treatment via single intravenous infusion. Intellia operates through research collaborations with Regeneron Pharmaceuticals and others to expand its pipeline in liver-focused and emerging disease targets. The company is building commercial infrastructure in the United States to support anticipated product launches, pending regulatory approvals.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	68	58	36	52	33
Research and development	389	466	435	420	230
General and administrative	120	126	116	90	71
Total operating expenses	509	592	552	510	301
Operating loss	−441	−534	−515	−458	−268
Interest income	29	48	50	9	1
Change in fair value of investments, net	−899,000	−33	0	0	—
Loss from equity method investment	0	0	−16	−11	−1
Change in fair value of contingent consideration	0	0	−100,000	−13	0
Total other income, net	28	15	34	−16	−42,000
Net loss	−413	−519	−481	−474	−268
Net loss per share, basic	−3.81	−5.25	−5.42	−6.16	−3.78
Net loss per share, diluted	−3.81	−5.25	−5.42	−6.16	−3.78
Weighted average shares outstanding, basic	108	99	89	77	71
Weighted average shares outstanding, diluted	108	99	89	77	71
Unrealized gain on marketable securities	427,000	731,000	4	−2	−2
Other comprehensive gain from equity method investment	0	0	2	−3	—
Comprehensive loss	−412	−518	−476	−479	−271

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	155	189	227	524	123
Marketable securities	294	412	685	669	625
Accounts receivable	9	9	36	4	2
Prepaid expenses and other current assets	68	30	50	20	19
Total current assets	528	640	998	1,217	769
Marketable securities - noncurrent	155	260	100	69	337
Property and equipment, net	18	27	33	28	21
Operating lease right-of-use assets	106	219	115	133	79
Investments and other assets	36	44	43	41	30
Total assets	842	1,191	1,301	1,520	1,294
Accounts payable	20	15	7	5	10
Accrued expenses	50	55	67	61	43
Current portion of operating lease liability	26	20	19	17	9
Current portion of deferred revenue	7	21	22	44	64
Total current liabilities	104	111	115	127	126
Deferred revenue, net of current portion	0	18	39	20	63
Long-term operating lease liability	67	190	97	114	65
Total liabilities	171	319	251	285	—
Commitments and contingencies (Note 6)	—	—	—	—	—
Common stock, $0.0001 par value; 240,000,000 shares authorized at December 31, 2025 and December 31, 2024; 116,317,060 and 102,029,594 shares issued and outstanding at at December 31, 2025 and December 31, 2024, respectively	12,000	10,000	9,000	9,000	7,000
Additional paid-in capital	3,260	3,049	2,711	2,420	1,746
Accumulated other comprehensive income	1	605,000	−2	−7	−3
Accumulated deficit	−2,590	−2,177	−1,658	−1,177	−703
Total stockholders equity	671	872	1,050	1,236	1,040
Total liabilities and stockholders' equity	842	1,191	1,301	1,520	1,294

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−413	−519	−481	−474	−268
Depreciation and amortization	10	10	9	8	7
Loss (gain) on disposal of property and equipment	527,000	−76,000	72,000	−162,000	0
Accelerated amortization/impairment of right-of-use assets	6	0	0	—	—
Stock-based compensation	80	154	134	91	47
Accretion of investment discounts and premiums	−6	−18	−26	4	8
(Recognition) deferral of equity method investment intra-entity profit on sales	0	−21	7	11	—
Accounts receivable	−951,000	28	−33	−2	99,000
Prepaid expenses and other current assets	−26	5	−27	−2	−10
Operating lease right-of-use assets	33	21	19	13	9
Other assets	3	917,000	−707,000	−1	117,000
Accounts payable	6	7	3	−5	529,000
Accrued expenses	−5	−10	6	16	17
Deferred revenue	−28	−22	−3	−63	−31
Operating lease liabilities	−55	−18	−17	−10	−9
Net cash used in operating activities	−395	−349	−394	−333	−225
Purchases of property and equipment	−1	−6	−14	−14	−13
Purchases of marketable securities	−323	−936	−904	−429	−1,021
Sales and maturities of marketable securities	552	1,067	887	648	486
Net cash provided by (used in) investing activities	228	126	−31	160	−551
Net proceeds from issuance of common stock	128	177	120	—	1,818
Proceeds from options exercised	722,000	6	7	15	41
Issuance of shares through employee stock purchase plan	3	3	4	3	2
Net cash provided by financing activities	131	186	130	583	737
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents	−35	−38	−295	410	−39
Purchases of property and equipment unpaid at period end	32,000	577,000	2	2	667,000
Reduction of right-of-use assets from remeasurement of lease liabilities	62	0	0	—	—
Operating lease liabilities arising from obtaining right-of-use assets	0	113	1	67	—
Non-cash trade-in of property and equipment	0	99,000	0	200,000	0
Proceeds from at-the-market offerings unpaid at period end	0	0	2	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Intellia Therapeutics, Inc.'s CIK number?

Intellia Therapeutics, Inc.'s SEC CIK number is 0001652130 (1652130). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Intellia Therapeutics, Inc.'s SEC filings?

All of Intellia Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Intellia Therapeutics, Inc. last report earnings?

Intellia Therapeutics, Inc. (NTLA) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-215721). This is Intellia Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Intellia Therapeutics, Inc.'s most recent earnings 8-K?

Intellia Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-215721. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Intellia Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →